Emily Girard

Emily Girard

Auto-generated profile, based on publicly available information

Emily Girard

The Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute , Seattle (S.M.M., E.J.G., E.E.C., K.B., M.C.B., H.C., J.M.O.)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Journal of Medical Imaging and Radiation Sciences
Verified
Journal Article
Closed access
CNChristopher Nuzzo
Christopher Nuzzo
EGEmily Girard
Emily Girard
WXWhitney Summer Xu
Whitney Summer Xu
LWLauren Wijaya
Lauren Wijaya
NKNareuchaya Karoonuthaisiri
Nareuchaya Karoonuthaisiri
YJYobelli Jimenez
Yobelli Jimenez

13 November 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
DMDeepak Kumar Mishra
Deepak Kumar Mishra
SMShelli M Morris
Shelli M Morris
DPDean Popovski
Dean Popovski
EGEmily J Girard
Emily J Girard
ABAndrew Bondoc
Andrew Bondoc
RDRachid Drissi
Rachid Drissi
BackgroundDespite intensive therapies, outcomes for high-risk pediatric brain tumors (PBTs) remain dismal, prompting the search for novel treatments. DNA methyltransferase inhibitors (DNMTi) have been shown to prime tumors to improve response to checkpoint inhibition. The aim of this study was to investigate the potential of decitabine (DAC), in combination with a PD-1 inhibitor, to improve survival in pediatric high-risk brain tumor models. Methods: Analysis of human PBT datasets was performed to determine gene expression levels of immune cell markers. Tumor response to DAC, with or without a PD-1 inhibitor, was tested in murine models representing H3-wildtype diffuse intrinsic pontine glioma (DIPG), H3K27-mutant diffuse midline glioma (DMG), atypical teratoid rhabdoid tumor (ATRT), and medulloblastoma (MB). CyTOF analysis of allograft tumors was performed to characterize changes within the tumor microenvironment. Results: Analysis of PBT subtypes revealed heterogeneous expression of immune cell markers, checkpoint receptors, and MHC molecules. DAC treatment decreased DNA methylation and increased neoantigen expression in human and mouse tumor cells. DAC treatment resulted in prolonged survival in syngeneic mouse models of DIPG and ATRT but not DMG and MB models. However, no added survival benefit was observed when combined with a PD-1 inhibitor. CyTOF analysis of mouse tumors revealed changes in local immune cell infiltration. Conclusions: DAC alone or in combination with a checkpoint inhibitor can alter the immune microenvironment in mouse tumor models. Changes were observed in H3-wildtype DIPG and ATRT models, suggesting that certain tumor subtypes may respond to immune priming with DNMTi.